Gujarat Terce Laboratories Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Gujarat Terce Laboratories Ltd is ₹ 39.34 as of 04 May 10:14 . The P/E Ratio of Gujarat Terce Laboratories Ltd changed from 22.2 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Novartis India Ltd changed from 65.2 on March 2021 to 19.2 on March 2025 . This represents a CAGR of -21.69% over 5 years The Market Cap of Gujarat Terce Laboratories Ltd changed from ₹ 5.16 crore on March 2021 to ₹ 45.37 crore on March 2025 . This represents a CAGR of 54.46% over 5 yearsThe Market Cap of Novartis India Ltd changed from ₹ 1362 crore on March 2021 to ₹ 1938 crore on March 2025 . This represents a CAGR of 7.30% over 5 years The revenue of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 12.42 crore as compare to the Sep '25 revenue of ₹ 12.98 crore. This represent the decline of -4.31% The revenue of Novartis India Ltd for the Dec '25 is ₹ 94.65 crore as compare to the Sep '25 revenue of ₹ 99.73 crore. This represent the decline of -5.09% The ebitda of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 1.26 crore as compare to the Sep '25 ebitda of ₹ 1.94 crore. This represent the decline of -35.05% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 31.11 crore as compare to the Sep '25 ebitda of ₹ 33.28 crore. This represent the decline of -6.52% The net profit of Gujarat Terce Laboratories Ltd changed from ₹ -0.08 crore to ₹ 0.76 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Novartis India Ltd changed from ₹ 25.74 crore to ₹ 16.09 crore over 7 quarters. This represents a CAGR of -23.55% The Dividend Payout of Gujarat Terce Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Limited, incorporated in 1985, produces branded generic formulations for the domestic market.
Over its more than three-decade business journey, the Company developed an extensive product basket comprising 50 brands covering multiple therapeutic areas which are marketed by its 180+ strong MR team across 13 Indian states.
Headquartered in Ahmedabad, the Company has its fully automated facility at Chhatral, in Gandhinagar, Gujarat By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing.
In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange.
In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Gujarat Terce Laboratories Ltd and Novartis India Ltd

Which company has a larger market capitalization, Gujarat Terce Laboratories Ltd or Novartis India Ltd?

Market cap of Gujarat Terce Laboratories Ltd is 29 Cr while Market cap of Novartis India Ltd is 2,550 Cr

What are the key factors driving the stock performance of Gujarat Terce Laboratories Ltd and Novartis India Ltd?

The stock performance of Gujarat Terce Laboratories Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Terce Laboratories Ltd and Novartis India Ltd?

As of May 4, 2026, the Gujarat Terce Laboratories Ltd stock price is INR ₹37.61. On the other hand, Novartis India Ltd stock price is INR ₹1032.9.

How do dividend payouts of Gujarat Terce Laboratories Ltd and Novartis India Ltd compare?

To compare the dividend payouts of Gujarat Terce Laboratories Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.